TerminatedNot Applicable

Effect of Pegvisomant on GH/IGF-I Relationship in GHD

Stopped: recruitment completed

United KingdomStarted 2004-12

Plain-language summary

Approximately 50% of middle-aged patients with severe AGHD have a normal age-related serum IGF-I. It remains unclear if in these individuals serum IGF-I is GH dependent or independent. This study compared the relationship between GH and serum IGF-I in two cohorts of male patients with severe AGHD; one with normal and the other with subnormal age-related serum IGF-I values. The GH receptor antagonist - pegvisomant was be used to specifically inhibit GH action and the changes in markers of the GH axis, such as serum IGF-I, IGFBP-3, GH and GHBP were measured.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Over 18 years of age * Confirmed severe AGHD * GH response \<9 mU/l (preferably \<4) to insulin-induced hypoglycaemia or glucagon stimulation test plus (These tests will have taken place as part of routine management). * Full, stable pituitary replacement therapy * Willing to provide informed consent Exclusion Criteria: * Unwilling to provide written consent * Current GH therapy * Pharmacological doses of glucocorticoids * Any acute illness

What they're measuring

change in IGF-I

Timeframe: 2 weeks per limb

Trial details

NCT IDNCT00468624

SponsorThe Christie NHS Foundation Trust

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Severe Adult Growth Hormone Deficiency trials